论文部分内容阅读
目的检测胃癌患者血清中可溶性B7-H4(sB7-H4)的水平并探讨其临床意义。方法应用酶联免疫吸附试验(ELISA)夹心法检测61例胃癌患者与51例正常人血清sB7-H4水平,分析其与病理类型、治疗前后、胃癌其他血清标志物的相关性。结果胃癌患者血清sB7-H4水平(49.14±16.16)μg/L明显高于正常人(32.67±12.28)μg/L,P<0.01。低分化腺癌患者sB7-H4水平(64.51±20.67)μg/L高于高分化腺癌(36.78±13.39)μg/L、粘液腺癌(42.79±12.31)μg/L和印戒细胞癌(44.62±12.27)μg/L,P<0.05。手术前胃癌患者血清sB7-H4水平(58.09±15.28)μg/L明显高于术后(38.58±9.49)μg/L,P<0.01。胃癌患者血清sB7-H4水平与CEA、CA19-9水平呈正相关(P<0.01)。结论胃癌患者血清中高水平的sB7-H4及其与病理类型、治疗情况、及其他肿瘤标志物相关,提示sB7-H4可能在胃癌的发生发展中有重要作用,可为胃癌的诊断和治疗提供一种新的靶位点。
Objective To detect the serum level of soluble B7-H4 (sB7-H4) in patients with gastric cancer and to explore its clinical significance. Methods Serum levels of sB7-H4 were detected by enzyme-linked immunosorbent assay (ELISA) in 61 patients with gastric cancer and 51 normal controls. The correlations were analyzed with pathological types, before and after treatment, and other serum markers of gastric cancer. Results Serum levels of sB7-H4 in gastric cancer patients (49.14 ± 16.16 μg / L) were significantly higher than those in normal controls (32.67 ± 12.28 μg / L, P <0.01). The sB7-H4 level in patients with poorly differentiated adenocarcinoma (64.51 ± 20.67) μg / L was significantly higher than that in well-differentiated adenocarcinoma (36.78 ± 13.39) μg / L, 42.79 ± 12.31 μg / L and signet ring cell carcinoma ± 12.27) μg / L, P <0.05. The serum level of sB7-H4 in patients with gastric cancer before surgery (58.09 ± 15.28) μg / L was significantly higher than that after operation (38.58 ± 9.49) μg / L, P <0.01. Serum sB7-H4 level in gastric cancer patients was positively correlated with CEA and CA19-9 (P <0.01). Conclusion The high level of sB7-H4 in serum of patients with gastric cancer and its relationship with pathological types, treatment, and other tumor markers suggest that sB7-H4 may play an important role in the development of gastric cancer and may provide a diagnosis and treatment of gastric cancer New target site.